AR and prostate cancer: Accordingly, it has been reported that FOXH1 can act as a hormone-independent corepressor of AR in prostate cancer cells; indeed, a protein-protein interaction was identified between the AR AF-1 domain and FOXH1 independently of the presence of dihydrotestosterone (109).